WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406543

CAS#: 1004551-40-9

Description: BMS-593214 is an active-site, direct FVIIa inhibitor. BMS-593214 displayed direct, competitive inhibition of human FVIIa in the hydrolysis of a tripeptide substrate with Ki of 5 nM. However, it acted as a noncompetitive inhibitor of the activation of the physiological substrate FX by TF/VIIa with Ki of 9.3 nM. BMS-593214 showed selectivity for FVIIa and exhibited species differences in TF-FVIIa-dependent anticoagulation with similar potency in human and rabbit plasma. BMS-593214 was efficacious in the prevention and treatment models of AT and VT with ED50 values of 1.1 to 3.1 mg/kg. Furthermore, BMS-593214 exhibited a wide therapeutic window with respect to BT. These results suggest that inhibition of FVIIa with small-molecule active-site inhibitors represents a promising antithrombotic approach for the development of new therapies for the prevention and treatment of AT and VT.

Chemical Structure

CAS# 1004551-40-9

Theoretical Analysis

MedKoo Cat#: 406543
Name: BMS-593214
CAS#: 1004551-40-9
Chemical Formula: C31H27N3O4
Exact Mass: 505.20016
Molecular Weight: 505.56
Elemental Analysis: C, 73.65; H, 5.38; N, 8.31; O, 12.66

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: BMS593214; BMS 593214; BMS-593214.

IUPAC/Chemical Name: 2'-((6R,6aR,11bR)-2-carbamimidoyl-6,6a,7,11b-tetrahydro-5H-indeno[2,1-c]quinolin-6-yl)-5'-hydroxy-4'-methoxy-[1,1'-biphenyl]-4-carboxylic acid.


InChi Code: InChI=1S/C31H27N3O4/c1-38-27-15-22(21(14-26(27)35)16-6-8-17(9-7-16)31(36)37)29-24-12-18-4-2-3-5-20(18)28(24)23-13-19(30(32)33)10-11-25(23)34-29/h2-11,13-15,24,28-29,34-35H,12H2,1H3,(H3,32,33)(H,36,37)/t24-,28-,29+/m1/s1

SMILES Code: O=C(C1=CC=C(C2=CC(O)=C(OC)C=C2[C@@H]3NC4=C(C=C(C(N)=N)C=C4)[C@]5([H])[C@@]3([H])CC6=C5C=CC=C6)C=C1)O

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 505.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Priestley ES, De Lucca I, Zhou J, Zhou J, Saiah E, Stanton R, Robinson L, Luettgen JM, Wei A, Wen X, Knabb RM, Wong PC, Wexler RR. Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor. Bioorg Med Chem Lett. 2013 Apr 15;23(8):2432-5. doi: 10.1016/j.bmcl.2013.02.013. Epub 2013 Feb 14. PubMed PMID: 23478148.

2: Aditya S. Oral and parenteral anticoagulants: new kids on the block. J Postgrad Med. 2012 Oct-Dec;58(4):275-85. doi: 10.4103/0022-3859.105448. Review. PubMed PMID: 23298923.

3: Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. doi: 10.1177/1753944710387808. Epub 2010 Nov 2. Review. PubMed PMID: 21045018.

4: Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010 Aug;104(2):302-10. doi: 10.1160/TH10-02-0097. Epub 2010 Jun 29. PubMed PMID: 20589316.

5: Wong PC, Luettgen JM, Rendina AR, Kettner CA, Xin B, Knabb RM, Wexler R, Priestley ES. BMS-593214, an active site-directed factor VIIa inhibitor: enzyme kinetics, antithrombotic and antihaemostatic studies. Thromb Haemost. 2010 Aug;104(2):261-9. doi: 10.1160/TH10-01-0025. Epub 2010 Jun 29. PubMed PMID: 20589312.

Additional Information